Participants with locally advanced or metastatic, relapsed/refractory, solid tumors harboring a SMARCA4 loss-of-function mutation that have progressed on, are intolerant of, or not otherwise candidates for available approved therapies
Adequate liver bone marrow, coagulation, renal, and cardiopulmonary function
Measurable disease per RECIST 1.1
ECOG PS of 0 or 1
You may not be if
Germline SMARCA4 mutations
Known SMARCA2 mutation or loss of expression
Symptomatic CNS disease
Prior treatment with another SMARCA2-directed therapy
History of other malignancies
Clinically significant heart disease
Uncontrolled hypertension
Prolongation of QT interval
Clareo Health | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
